The One Big Beautiful Bill Act takes a big step in the rare disease space by expanding the contours of the orphan drug ...

As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the ...

The One Big Beautiful Bill Act ("OBBB") expands exemptions for orphan drugs from mandatory Medicare price negotiations and modifies their ...

Earlier this year, President Trump issued an executive order pledging “immediate steps to end global freeloading” and “aggressive action” to ensure drugmakers “offer American consumers the ...

The number rises to 20 negotiated medications a year starting in 2029. The government will only select Medicare Part D drugs for the first two round of negotiations.

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

The changes are part of the Act, which was approved in Congress in 2022 and signed into law by President Joe Biden. It resulted in negotiations between Medicare and big pharma for 10 drugs. In 2025, ...

The Senate Parliamentarian reversed course on a small provision in the One Big Beautiful Bill Act that could boost cures for rare diseases.

Medicare Part D premiums will increase next year, the Centers for Medicare & Medicaid Services (CMS) announced as the agency adjusts a Biden-era program. | The Trump administration is also modifying ...

Medicare drug price negotiation is still relatively new. Until the 2022 passage of the Inflation Reduction Act, Medicare Part D, which covers more than 50 million seniors, didn't have the ...